TWI907406B - 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法 - Google Patents
使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法Info
- Publication number
- TWI907406B TWI907406B TW110112266A TW110112266A TWI907406B TW I907406 B TWI907406 B TW I907406B TW 110112266 A TW110112266 A TW 110112266A TW 110112266 A TW110112266 A TW 110112266A TW I907406 B TWI907406 B TW I907406B
- Authority
- TW
- Taiwan
- Prior art keywords
- fenibrutinib
- individual
- acceptable salt
- pharmaceutically acceptable
- baseline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US63/005,095 | 2020-04-03 | ||
| US202063051767P | 2020-07-14 | 2020-07-14 | |
| US63/051,767 | 2020-07-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202203925A TW202203925A (zh) | 2022-02-01 |
| TWI907406B true TWI907406B (zh) | 2025-12-11 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110112266A TWI907406B (zh) | 2020-04-03 | 2021-04-01 | 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12605376B2 (https=) |
| EP (1) | EP4125906A1 (https=) |
| JP (1) | JP2023520469A (https=) |
| KR (1) | KR20220163986A (https=) |
| CN (1) | CN115916205A (https=) |
| AU (1) | AU2021249129A1 (https=) |
| BR (1) | BR112022019846A2 (https=) |
| CA (1) | CA3177390A1 (https=) |
| CL (1) | CL2022002699A1 (https=) |
| IL (1) | IL296990A (https=) |
| MX (1) | MX2022012310A (https=) |
| TW (1) | TWI907406B (https=) |
| WO (1) | WO2021202825A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010513A (es) * | 2020-02-28 | 2022-09-21 | Genentech Inc | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. |
| KR102933902B1 (ko) | 2021-05-14 | 2026-03-05 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 공결정질 형태 |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
| WO2024238524A1 (en) * | 2023-05-16 | 2024-11-21 | Genentech, Inc. | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| SG11201700849XA (en) | 2014-08-07 | 2017-03-30 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
| EP4049660B1 (en) | 2016-02-29 | 2025-02-19 | F. Hoffmann-La Roche AG | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CN107043366B (zh) | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| MX393601B (es) | 2017-05-18 | 2025-03-21 | Jiangsu Hengrui Medicine Co | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| CN112512527A (zh) * | 2018-09-12 | 2021-03-16 | 杭州索元生物医药股份有限公司 | 恩扎妥林和btk抑制剂的组合及其用途 |
| CN113423401A (zh) | 2019-01-22 | 2021-09-21 | 豪夫迈·罗氏有限公司 | 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法 |
| MX2022010513A (es) | 2020-02-28 | 2022-09-21 | Genentech Inc | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. |
-
2021
- 2021-04-01 AU AU2021249129A patent/AU2021249129A1/en active Pending
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 TW TW110112266A patent/TWI907406B/zh active
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en not_active Ceased
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko active Pending
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 US US17/995,259 patent/US12605376B2/en active Active
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Non-Patent Citations (1)
| Title |
|---|
| 期刊 JJ Crawford et al. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development 61(6) J. Med. Chem February 2018 2227−2245 |
Also Published As
| Publication number | Publication date |
|---|---|
| US12605376B2 (en) | 2026-04-21 |
| KR20220163986A (ko) | 2022-12-12 |
| BR112022019846A2 (pt) | 2022-11-22 |
| CA3177390A1 (en) | 2021-10-07 |
| WO2021202825A1 (en) | 2021-10-07 |
| MX2022012310A (es) | 2022-10-27 |
| CN115916205A (zh) | 2023-04-04 |
| US20230149395A1 (en) | 2023-05-18 |
| IL296990A (en) | 2022-12-01 |
| EP4125906A1 (en) | 2023-02-08 |
| TW202203925A (zh) | 2022-02-01 |
| CL2022002699A1 (es) | 2023-03-31 |
| JP2023520469A (ja) | 2023-05-17 |
| AU2021249129A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI907406B (zh) | 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法 | |
| TWI794885B (zh) | 全身紅斑性狼瘡之治療 | |
| US11123329B1 (en) | Use of angiotensin II type 2 receptor agonist | |
| JP2021181501A (ja) | 免疫不全疾患を処置するための方法 | |
| TWI899163B (zh) | 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 | |
| CN109562280B (zh) | 复发-缓解型多发性硬化的诊断或预测因子 | |
| EP3376869B1 (en) | Treatment of autoimmune disease | |
| RU2858695C2 (ru) | Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона | |
| WO2025045766A1 (en) | Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same | |
| TW202517276A (zh) | 用於治療自體免疫及發炎疾病之rip1激酶抑制劑之調配物及劑量療法 | |
| RU2858696C2 (ru) | Способы лечения первично-прогрессирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона | |
| HK40087403A (zh) | 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法 | |
| HK40082153A (en) | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase | |
| US12600715B2 (en) | Soluble guanylate cyclate activators for treating systemic sclerosis | |
| TW202430217A (zh) | 用於免疫介導之壞死性肌病變之治療及預防的抗ｃｄ１９結合劑 | |
| EP4630003A1 (en) | Methods for treating immune thrombocytopenia in subjects with cognitive impairment by administering rilzabrutinib | |
| WO2024126431A1 (en) | Anti-ilt7 binding agents for the treatment and prevention of myositis |